drugset / Trial / NCT00120133

Atorvastatin (Lipitor) to Prevent Bone Pain

NCT00120133

RandomizedCrossoverDouble-blindPrevention

Summary

In the proposed randomized double blind cross-over placebo controlled study, the researchers intend to investigate if Atorvastatin (FDA approved statin for children) can be used to alleviate the symptom of bone pain (acute phase reaction) that is commonly associated with initial doses of pamidronate or zoledronic acid, and also the mechanism that underlies this proposed beneficial effect of Atorvastatin. The primary outcome studied will be alleviation of bone pain by Atorvastatin compared to placebo by visual analogue pain scale in children treated with pamidronate or zoledronic acid. The secondary outcome investigated will be changes in blood count and γδT cell count, C-reactive protein (CRP) and cytokine levels of interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-α) and gamma interferon (γ-IFN) following treatment with Atorvastatin compared to placebo.

Timeline

Start
2004-12
Primary completion
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 10 mg Oral

Indications